Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2017

01-01-2017 | Special Article

2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Authors: Lawrence H. Einhorn, Bernardo Rapoport, Rudolph M. Navari, Jørn Herrstedt, Mary J. Brames

Published in: Supportive Care in Cancer | Issue 1/2017

Login to get access

Abstract

Purpose

This review summarizes the recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting as agreed at the MASCC/ESMO Antiemetic Guidelines update meeting in Copenhagen in June 2015.

Methods

A systematic literature search using PubMed from January 01, 2009 through January 06, 2015 with a restriction to papers in English was conducted.

Results

There were three phase III randomized trials in patients undergoing high-dose chemotherapy and stem cell transplant and eight single arm non-randomized clinical studies (single in patients undergoing transplantation and one in patients receiving multiple-day chemotherapy treatment). We used a total of two randomized clinical trials in this guideline update. For patients receiving treatment for breakthrough chemotherapy-induced nausea and vomiting, a phase III randomized trial investigating the use of olanzapine versus metoclopramide in patients receiving highly emetogenic chemotherapy and a second single arm study looking at the effectiveness of olanzapine were identified.

Conclusions

It was concluded that for patients receiving high-dose chemotherapy with stem cell transplant, a combination of a 5-HT3 receptor antagonist with dexamethasone and aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4) is recommended before chemotherapy.
For patients undergoing multiple-day chemotherapy-induced nausea and vomiting, a 5-HT3 receptor antagonist, dexamethasone, and aprepitant, are recommended before chemotherapy for the prophylaxis of acute emesis and delayed emesis.
For patients experiencing breakthrough nausea and vomiting, the available evidence suggests the use of 10 mg oral olanzapine, daily for 3 days. Mild to moderate sedation in this patient population (especially elderly patients) is a potential problem with this agent.
Literature
1.
Einhorn LH, Grunberg SM, Rapoport B et al (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 19(Suppl 1):S1–S4CrossRefPubMed
2.
Svanberg A, Birgegård G (2015) Addition of aprepitant (Emend®) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89:31–36CrossRefPubMed
3.
Schmitt T, Goldschmidt H, Neben K et al (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413–3420CrossRefPubMed
4.
Bechtel T, McBride A, Crawford B et al (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 22:2911–2916CrossRefPubMed
5.
Sakurai M, Mori T, Kato J et al (2014) Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation. Int J Hematol 99:457–462CrossRefPubMed
6.
Uchida M, Ikesue H, Miyamoto T et al (2013) Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819–824CrossRefPubMed
7.
Stiff PJ, Fox-Geiman MP, Kiley K et al (2013) Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49–55CrossRefPubMed
8.
Pielichowski W, Gawronski K, Mlot B et al (2011) Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J Buon 3:541–546
9.
Pielichowski W, Barzal J, Gawronski K et al (2011) A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43:3107–3110CrossRefPubMed
10.
Giralt SA, Mangan KF, Maziarz RT et al (2011) Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 22:939–946CrossRefPubMed
11.
Rzepecki P, Pielichowski W, Oborska S et al (2009) Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience. Transplant Proc 41:3247–3249CrossRefPubMed
12.
Paul B, Trovato JA, Thompson J et al (2010) Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 16:45–51CrossRefPubMed
13.
Musso M, Scalone R, Crescimanno A et al (2010) Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 45:123–127CrossRefPubMed
14.
Albany C, Brames MJ, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group Study. J Clin Oncol 30:3998–4003CrossRefPubMed
15.
Olver I, Grimson P, Chatfield M et al (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in a 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21:1561–1568CrossRefPubMed
16.
Hamada S, Hinotsu S, Kawaj K et al (2014) Antiemetic efficacy and safety of a combination of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 22:2161–2166CrossRefPubMed
17.
Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663CrossRefPubMed
18.
Chanthawong S, Subongkot S, Sookprasert A (2014) Effective of olanzapine for the treatment of breakthrough chemotherapy-induced nausea and vomiting. J Med Assoc Thail 97:349–355
19.
Vig S, Seibert L, Green MR (2014) Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol 140:77–82CrossRefPubMed
20.
Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 2014(22):1143–1151CrossRef
21.
Egerer G, Eisenlohr K, Gronkowski M et al (2010) The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 70:903–907CrossRefPubMedPubMedCentral
22.
Einhorn LH, Rapoport B, Koeller J et al (2005) Antiemetic therapy for multiple-day chemotherapy and high dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112–116CrossRefPubMed
23.
Somerfield MR, Einhaus K, Hagerty KL et al (2008) ASCO clinical practice guidelines: opportunities and challenges. J Clin Oncol 26:4022–4026CrossRefPubMed
24.
Einhorn LH, Nagy C, Werner K et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731–735PubMed
25.
Herman TS, Einhorn LH, Jones SE et al (1979) Superiority of nabilone over prochlorperazine as antiemetics in patients receiving chemotherapy. N Engl J Med 300:1295–1297CrossRefPubMed
26.
Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391–2395PubMed
27.
Herrstedt J, Sigsgaard TC, Nielsen HA et al (2007) Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15:417–426CrossRefPubMed
28.
Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015CrossRefPubMedPubMedCentral
29.
Cook AM, Dzik-Jurasz ASK, Padhami AR et al (2001) The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumors. Br J Cancer 85:1624–1626CrossRefPubMedPubMedCentral
30.
Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293–1300CrossRefPubMed
Metadata
Title
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Authors
Lawrence H. Einhorn
Bernardo Rapoport
Rudolph M. Navari
Jørn Herrstedt
Mary J. Brames
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3449-y

Other articles of this Issue 1/2017

Supportive Care in Cancer 1/2017 Go to the issue

Original Article

A tiered multidisciplinary approach to the psychosocial care of adult cancer patients integrated into routine care: the PROMPT study (a cluster-randomised controlled trial)

Original Article

Psychological distress of cancer patients with children under 18 years and their partners—a longitudinal study of family relationships using dyadic data analysis

Erratum

Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Original Article

Feasibility of implementing the ‘Screening for Distress and Referral Need’ process in 23 Dutch hospitals

Original Article

Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design

Original Article

Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits